Conditions: Psoriasis
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 91
Healthy volunteers: no

Brief summary:
This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.

Detailed description:

Arms:
arm 1: Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.

Interventions: intervention 1: 80 mg ixekizumab
Intervention descriptions: intervention 1: Administered SC

Protocol document: